Protocol
10-162
Full Title
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally Advanced RCC Following Nephrectomy (VEG113387)
Purpose
Some patients with renal cell carcinoma (RCC) are able to have the tumor surgically removed from the kidney during an operation called nephrectomy. However, if the tumor is determined to be of a high stage, there is a greater risk of recurrence.
Pazopanib is a drug approved for the treatment of RCC which has spread to other parts of the body. The purpose of this study is to see if pazopanib can help reduce the risk of recurrence in patients with localized or locally advanced RCC who had nephrectomy.
Pazopanib is a tablet that is taken orally (by mouth). Patients will be randomly assigned to receive pazopanib or a placebo (sugar pill).
Investigator
Co-Investigators
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have localized or locally advanced RCC that has been surgically removed through radical or partial nephrectomy.
- Patients must not have evidence of disease spread (metastasis).
- Patients may not have had prior chemotherapy or radiation therapy before or after surgery.
- Patients must be age 18 or older
For more information about this study and to inquire about eligibility, please contact Dr. Robert Motzer at 646-422-4312.
Disease(s)
Kidney Cancer
Locations
Related Diseases
